BOCA RATON, Fla., Jan. 31, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for oncology and non-oncology conditions, announces the following promotions, all effective immediately:
Vice President and General Counsel Michael J. Sardano was promoted to President and General Counsel. Sales Manager Christopher Machuzak has been promoted to Vice President of West Coast Sales.
In addition, the Company announces the retirement of Steve Cohen, Executive Vice President and Co-Founder, also effective immediately.
“We are making these leadership changes to prepare Sensus Healthcare for sustained long-term growth and commercial success. It is a testament to our organization that we have such exceptional talent within our ranks and are able to promote from within to create a winning leadership team,” said Joe Sardano, President and CEO of Sensus.
Michael Sardano joined Sensus in 2013 as Corporate Counsel for Regulatory Affairs and Manager of Compliance. He added corporate governance to his responsibilities in 2016, was promoted to general counsel in 2017, and vice president and general counsel in 2019. He previously served as a legal intern with the Massachusetts Department of Revenue Appeals Office and an intern at Senate. for the Rules and Administration Committee of Senator Lamar Alexander’s office. Mr. Sardano holds a JD from New England Law and a BS in Management and Finance from Bentley University. He was admitted to the Florida Bar in 2014.
“Michael’s performance on behalf of Sensus Healthcare has always been exceptional,” commented Mr. Sardano. “He was instrumental in the favorable reevaluation of the Centers for Medicare and Medicaid Services Superficial Radiation Therapy reimbursement codes in January 2021, which has since contributed to our sales growth. He worked tirelessly on regulatory issues, adding radiation therapy licenses from a growing number of states. I am very pleased that the Sensus Healthcare Board of Directors has identified Michael for this leadership position and I am duly proud of my son.
Christopher Machuzak joined Sensus in 2012 as Account Executive and was promoted to Director of Sales in 2017. He was previously Territory Manager at Dermpath Diagnostics. Mr. Machuzak earned a BS in Education from Mansfield University in Pennsylvania.
Jeffrey Starling was hired by Sensus as Southwest Account Manager in 2016 and was promoted to Southeast Regional Manager in 2020. He previously served as Business Development Manager at Fallene Cosmeceutical, Ltd. and held various sales and business development positions at Biopelle, Inc. He holds a bachelor’s degree in marketing communications from Southern Methodist University.
“On behalf of the Sensus Board of Directors, I extend my congratulations to Chris and Jeff on their well-deserved promotions,” continued Mr. Sardano. “Both have been instrumental in resuming robust sales growth, maintaining customer relationships during the COVID-19 pandemic and growing the customer base throughout 2021. We look forward to their continued leadership in sales.”
Commenting on the departure of Steve Cohen, Mr. Sardano added: “Along with the entire Sensus team, I wish Steve the best in his retirement. Steve and I co-founded Sensus over ten years ago, having worked together before. We are grateful to Steve for his skillful leadership of the sales and marketing functions and for creating the sales organization we have today which is so promising. On a personal note, Steve has been a trusted friend and colleague for many years, and I will miss him dearly.
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for oncology and non-oncology conditions. The Sculptura™ Modulated Robotic Brachytherapy Radiation Oncology System provides targeted directional anisotropic radiation therapy (ART) and brachytherapy using our proprietary 3D Beam Sculpting™ technology to treat patients undergoing cancer treatment during surgery or at the site tumor, fast and efficient. Sensus also offers its proprietary low-energy X-ray technology known as Superficial Radiation Therapy (SRT), which is the culmination of over a decade of research and development, to treat skin cancers other than melanomas and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™. With its portfolio of innovative medical devices, Sensus offers breakthrough treatment options to improve the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
This press release contains statements that are or may be deemed to be “forward-looking statements”. In some cases, these statements can be identified by the use of forward-looking terms such as “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, ” may”, “could”, “could”, “will”, “should”, “approximately”, “potential” or negative or other variations of these terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments and circumstances relating to Sensus, our industry and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timeframes. provided that. Although we believe we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development industry conditions in which we operate may differ materially from the forward-looking statements contained in this press release due to, among other things, the following factors: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and retain the intellectual property necessary to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third-party payer reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement decreases; regulatory requirements applicable to us and our competitors; our ability to effectively manage our manufacturing processes and costs; risks arising from our international operations; laws, regulations or other government action affecting our products, taxes, international trade regulations or other aspects of our business; the concentration of our customers in the United States and China, including the concentration of sales to a particular customer in the United States; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
Furthermore, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements we make in this press release speak only as of the date of this statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this release. release, except as may be required by applicable law. You should carefully read our “Caution Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our activities.
Contact: LHA Investor Relations Kim Sutton Golodetz 212-838-3777 [email protected]
# # #